This week, we will discuss another IgA Nephropathy trial - Sparsentan this time. A dual endothelin antagonist and angiotensin receptor antagonist.
PROTECT study on Sparsentan in IgAN - Visual Abstract
Is Sparsentan effective and safe for patients with IgAN on maximal Raas blockade? Check out the VA by NSMC intern Saumya Vishnoi